Tests MZE829 in adults with APOL1-related protein-leaking kidney disease
Tests the drug MZE829 in adults with kidney disease linked to the APOL1 gene.
Key facts
- Who runs it
- Maze Therapeutics
- Where
- Créteil, Lille, Lyon, Paris, and Saint-Ouen, FranceSee the 5 sitesAlso in 2 other countries, 61 sites
- Trial code
- Registry title
- A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 74 people, planned
- Started
- 5 Feb 2025
- Planned end
- Sept 2026
- Type of study
- Interventional
- Treatments tested
- MZE829
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term kidney disease and protein in the urine who carry a high-risk APOL1 gene type.
- Age
- 18 Years to 68 Years
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease with persistent albuminuria (protein in the urine).
- Biomarker or test result
- APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2.
Main reasons for not taking part
- Organ or bone marrow transplantation
- Active cancer within the past 2 years (some treated early cancers are allowed)
- Conditions that may change how the drug is absorbed, such as bariatric surgery
- Type I diabetes
- Pregnant or currently nursing
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
- Chronic kidney disease with persistent albuminuria
Who cannot take part
- Organ or bone marrow transplantation
- History of active cancer within past 2 years, except for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
- Conditions that may alter drug absorption, e.g., history of bariatric surgery
- Type I diabetes
- Pregnant or currently nursing; Other inclusion/exclusion criteria defined in protocol apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 68 years old?
Where in France
Also in 2 other countries, 61 sites
- CréteilHospital not named in the registryContact: Maze TherapeuticsTaking people
- LilleHospital not named in the registryContact: Maze TherapeuticsTaking people
- LyonHospital not named in the registryContact: Maze TherapeuticsTaking people
- ParisHospital not named in the registryContact: Maze TherapeuticsTaking people
- Saint-OuenHospital not named in the registryContact: Maze TherapeuticsTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
The group in the trial
- MZE829Treatment being tested
Cohort 1: Chronic kidney disease with concurrent diabetes Cohort 2: Chronic kidney disease without concurrent diabetes
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults With Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
- Plain-language title
- Tests MZE829 in adults with APOL1-related protein-leaking kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06830629, who can take part
- Record updated
- 27 July 2026